Literature DB >> 25834341

Effects of neutrophil elastase inhibitor in patients undergoing esophagectomy: a systematic review and meta-analysis.

Zhi-Qiang Wang1, Long-Qi Chen1, Yong Yuan1, Wen-Ping Wang1, Zhong-Xi Niu1, Yu-Shang Yang1, Jie Cai1.   

Abstract

AIM: To evaluate the benefit and safety of sivelestat (a neutrophil elastase inhibitor) administration in patients undergoing esophagectomy.
METHODS: Online databases including PubMed, EMBASE, the Cochrane Library, Web of Knowledge, and Chinese databases (Wanfang database, VIP and CNKI) were searched systematically up to November 2013. Randomized controlled trials and high-quality comparative studies were considered eligible for inclusion. Three reviewers evaluated the methodological quality of the included studies, and Stata 12.0 software was used to analyze the extracted data. The risk ratio (RR) was used to express the effect size of dichotomous outcomes, and mean difference (MD) or standardized mean difference was used to express the effect size of continuous outcomes.
RESULTS: Thirteen studies were included in this systematic review and nine studies were included in the meta-analysis. The duration of mechanical ventilation was significantly decreased in the sivelestat group on postoperative day 5 [I (2) = 76.3%, SMD = -1.41, 95%CI: -2.63-(-0.19)]. Sivelestat greatly lowered the incidence of acute lung injury in patients after surgery (I (2) = 0%, RR = 0.27, 95%CI: 0.08-0.93). However, it did not decrease the incidence of pneumonia, intensive care unit stay or postoperative hospital stay, and did not increase the incidence of complications such as anastomotic leakage, recurrent nerve palsy, wound infection, sepsis and catheter-related fever.
CONCLUSION: A neutrophil elastase inhibitor is beneficial in patients undergoing esophagectomy. More high quality, large sample, multi-center and randomized controlled trials are needed to validate this effect.

Entities:  

Keywords:  Esophageal cancer; Esophagectomy; Meta-analysis; Neutrophil elastase inhibitor; Systematic review

Mesh:

Substances:

Year:  2015        PMID: 25834341      PMCID: PMC4375598          DOI: 10.3748/wjg.v21.i12.3720

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

1.  Effects of sivelestat on bronchial inflammatory responses after esophagectomy.

Authors:  Keisuke Yamaguchi; Yusuke Sugasawa; Kazuyo Takeuchi; Toyoki Kugimiya; Seiichiro Kumakura; Yoshimi Iwanuma; Yoshiaki Kajiyama; Masahiko Tsurumaru; Isao Nagaoka; Eiichi Inada
Journal:  Int J Mol Med       Date:  2011-05-06       Impact factor: 4.101

2.  The effects of the early administration of sivelestat sodium, a selective neutrophil elastase inhibitor, on the postoperative course after radical surgery for esophageal cancer.

Authors:  Junichi Nishiyama; Mitsumasa Matsuda; Satoko Ando; Miyoko Hirasawa; Toshiyasu Suzuki; Hiroyasu Makuuchi
Journal:  Surg Today       Date:  2011-12-27       Impact factor: 2.549

3.  Preventive effect of sivelestat on postoperative respiratory disorders after thoracic esophagectomy.

Authors:  Yohei Nagai; Masayuki Watanabe; Yoshihumi Baba; Masaaki Iwatsuki; Kotaro Hirashima; Ryuichi Karashima; Jyunji Kurashige; Koichi Kinoshita; Hideo Baba
Journal:  Surg Today       Date:  2013-02-15       Impact factor: 2.549

4.  Influence of neutrophil elastase inhibitor on the postoperative course in patients with esophageal cancer after transthoracic esophagectomy.

Authors:  Kenji Mimatsu; Takatsugu Oida; Atsushi Kawasaki; Hisao Kano; Youichi Kuboi; Sadao Amano
Journal:  Hepatogastroenterology       Date:  2011 Sep-Oct

5.  Perioperative use of a neutrophil elastase inhibitor in video-assisted thoracoscopic oesophagectomy for cancer.

Authors:  H Makino; C Kunisaki; T Kosaka; H Akiyama; S Morita; I Endo
Journal:  Br J Surg       Date:  2011-05-09       Impact factor: 6.939

6.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

7.  Optimal period for the prophylactic administration of neutrophil elastase inhibitor for patients with esophageal cancer undergoing esophagectomy.

Authors:  Makoto Iwahashi; Mikihito Nakamori; Masaki Nakamura; Toshiyasu Ojima; Teiji Naka; Hiroki Yamaue
Journal:  World J Surg       Date:  2011-07       Impact factor: 3.352

8.  Prospective randomized controlled study on the effects of perioperative administration of a neutrophil elastase inhibitor to patients undergoing video-assisted thoracoscopic surgery for thoracic esophageal cancer.

Authors:  Y Kawahara; I Ninomiya; T Fujimura; H Funaki; H Nakagawara; H Takamura; K Oyama; H Tajima; S Fushida; H Inaba; M Kayahara
Journal:  Dis Esophagus       Date:  2009-09-25       Impact factor: 3.429

9.  Sivelestat sodium hydrate reduces radiation-induced lung injury in mice by inhibiting neutrophil elastase.

Authors:  Nobuhiko Yoshikawa; Taisuke Inomata; Yoshikatsu Okada; Taiju Shimbo; Masatsugu Takahashi; Kazuhiko Akita; Yasuo Uesugi; Yoshifumi Narumi
Journal:  Mol Med Rep       Date:  2013-02-08       Impact factor: 2.952

10.  Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients.

Authors:  Mineji Hayakawa; Kenichi Katabami; Takeshi Wada; Masahiro Sugano; Hirokatsu Hoshino; Atsushi Sawamura; Satoshi Gando
Journal:  Shock       Date:  2010-01       Impact factor: 3.454

View more
  8 in total

1.  Prophylactic sivelestat for esophagectomy and in-hospital mortality: a propensity score-matched analysis of claims database.

Authors:  Chikashi Takeda; Masato Takeuchi; Yohei Kawasaki; Hiroshi Yonekura; Isao Nahara; Aki Kuwauchi; Satomi Yoshida; Shiro Tanaka; Koji Kawakami
Journal:  J Anesth       Date:  2019-01-05       Impact factor: 2.078

2.  Local inhibition of elastase reduces EMILIN1 cleavage reactivating lymphatic vessel function in a mouse lymphoedema model.

Authors:  Eliana Pivetta; Bruna Wassermann; Lisa Del Bel Belluz; Carla Danussi; Teresa Maria Elisa Modica; Orlando Maiorani; Giulia Bosisio; Francesco Boccardo; Vincenzo Canzonieri; Alfonso Colombatti; Paola Spessotto
Journal:  Clin Sci (Lond)       Date:  2016-02-26       Impact factor: 6.124

3.  Administration of Corticosteroids, Ascorbic Acid, and Thiamine Improves Oxygenation after Thoracoscopic Esophagectomy.

Authors:  Tadashi Matsuoka; Hiroharu Shinozaki; Soji Ozawa; Yoshimitsu Izawa; Kazuo Koyanagi; Alan Kawarai Lefor; Kenji Kobayashi
Journal:  Ann Thorac Cardiovasc Surg       Date:  2019-10-18       Impact factor: 1.520

4.  Neutrophil elastase inhibitor purification strategy from cowpea seeds.

Authors:  Graziele Cristina Ferreira; Adriana Feliciano Alves Duran; Flavia Ribeiro Santos da Silva; Livia de Moraes Bomediano; Gabriel Capella Machado; Sergio Daishi Sasaki
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

5.  Neutrophil Elastase Inhibitor Sivelestat Attenuates Myocardial Injury after Cardioplegic Arrest in Rat Hearts.

Authors:  Masahiro Fujii; Ryuzo Bessho
Journal:  Ann Thorac Cardiovasc Surg       Date:  2019-12-09       Impact factor: 1.520

6.  Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related Diseases.

Authors:  Xiaojie Chu; Zehua Sun; Du-San Baek; Wei Li; John W Mellors; Steven D Shapiro; Dimiter S Dimitrov
Journal:  Int J Mol Sci       Date:  2021-10-15       Impact factor: 5.923

Review 7.  Neutrophil Extracellular Traps in Cancer Therapy Resistance.

Authors:  Muhammad H Shahzad; Lixuan Feng; Xin Su; Ariane Brassard; Iqraa Dhoparee-Doomah; Lorenzo E Ferri; Jonathan D Spicer; Jonathan J Cools-Lartigue
Journal:  Cancers (Basel)       Date:  2022-03-07       Impact factor: 6.639

Review 8.  Risk factors and therapeutic measures for postoperative complications associated with esophagectomy.

Authors:  Mojtaba Ahmadinejad; Ali Soltanian; Leila Haji Maghsoudi
Journal:  Ann Med Surg (Lond)       Date:  2020-05-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.